Pulmocide is a UK-based biotechnology company developing a leading range of first-in-class inhaled anti-infectives for the targeted treatment of life-threatening lung infections.
Location: United Kingdom, England, London
Total raised: $174M
Investors 7
| Date | Name | Website |
| - | Jeito Capi... | jeito.life |
| - | F-Prime Ca... | fprimecapi... |
| - | Adjuvant C... | adjuvantca... |
| 23.01.2023 | Vivo Capit... | vivocapita... |
| - | SV Health ... | svhealthin... |
| - | Eight Road... | eightroads... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.12.2022 | - | $52M | - |
| 27.05.2021 | Series C | $92M | Jeito Capi... |
| 21.03.2017 | Series B | $30M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 06.12.2022 | Pulmocide Raises $52 Million to Fund Additional Late-Stage D... | - | fprimecapi... |
| 06.12.2022 | Pulmocide Ltd - Pulmocide Raises $52 Million to Fund Additio... | Strong support from high-quality new and existing investors provides capital for opelconazole deve... | ipgroupplc... |
| 06.12.2021 | CF Foundation Invests $3.5 Million in Pulmocide for Developm... | - | fprimecapi... |
| 27.05.2021 | Pulmocide Raises $92 million in a Series C Financing to Fund... | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London,... | marketscre... |
| 27.05.2021 | Jeito Capital leads oversubscribed $92 million Series C fina... | Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects P... | marketscre... |
| 27.05.2021 | IP GROUP PLC IP : Pulmocide Ltd - Raises $92 million in a S... | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled ther... | marketscre... |
| 27.05.2021 | IP : Pulmocide Ltd - Raises $92 million in a Series C financ... | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled ther... | marketscre... |
| 27.05.2021 | Pulmocide Raises $92 million in a Series C Financing to Fund... | London, UK, 27May2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company devel... | svhealthin... |
| 27.05.2021 | Pulmocide Raises $92 million in a Series C Financing to Fund... | - | fprimecapi... |
| 22.03.2017 | Term Sheet — Wednesday, March 22 | SCREAMING DOWN While sifting through the news I missed on my vacation, one deal stuck out to me for... | fortune.co... |
Show more